| Table 2. Comparison of ovarian stimulation data and outcomes between patients undergoing stimulation with rFSH or hp-hMG. | |||
| rFSH (n=341) |
hp-hMG (n=115) |
p value | |
|---|---|---|---|
| Ovarian stimulation protocol GnRH antagonist PPOS |
296 (86.8) 45 (13.2) |
87 (75.7) 28 (24.3) |
0.008 |
| Ovarian stimulation duration (days) | 11.33 (1.60) | 11.02 (1.46) | 0.265 |
| †GT total dose (mIU/mL) | 3157.36 (919.35) | 3263.48 (811.20) | 0.645 |
| †Peak E2 (pg/mL) | 2547.18 (1648.21) | 3468.02 (2497.69) | <0.001 |
| †Peak P (ng/mL) | 1.33 (0.75) | 1.01 (0.52) | 0.001 |
| Final maturation trigger GnRH agonist hCG hCG+GnRH agonist |
332 (97.4) 8 (2.3) 1 (0.3) |
105 (91.3) 9 (7.8) 1 (0.9) |
0.019 |
| †Oocytes retrieved (n) | 16.82 (10.95) | 13.25 (9.66) | 0.02 |
| †MII oocytes (n) | 13.22 (9.13) | 9.76 (7.11) | 0.005 |
| Maturity rate (%) | 77.98 (16.63) | 75.10 (21.22) | 0.103 |
*After ANCOVA with antral follicle count (AFC) as a covariate.
Values are presented as mean (standard deviation) or number (%). A p value of <0.05 was considered significant.
†The p value was calculated after log transformation for normal distribution.
rFSH, recombinant follicle-stimulating hormone; hp-hMG, highly purified-human menopausal gonadotropin; GnRH, gonadotropin-releasing hormone; PPOS, progestin-primed ovarian stimulation; GT, gonadotropins; E2, estradiol; P, progesterone; hCG, human chorionic gonadotropin; MII, metaphase II.